EIT Health-supported start-up, MOWOOT, has earned the first ever ‘US Food and Drug Administration Breakthrough Device Designation’ for a novel non-drug and non-invasive therapy of neurogenic bowel disorder.

EIT Health MOWOOT earns FDA device designation

Medical device company USMIMA S.L. (brand name MOWOOT), with headquarters in Barcelona, has announced that its first product “MOWOOT II Intestinal Transit Management System” has been granted Breakthrough Device Designation by the FDA.

FDA grants Breakthrough Designation to intestinal management system

Mowoot has recently opened a $2.3 million (€2 million) financing round to further develop, and to enter the German market. The company also intends to allocate capital in the Netherlands and the United Kingdom. Looking ahead to 2023, Mowoot intends to expand throughout the European Union, optimize processes and end up making the leap to the United States. 0
Mowoot is seeking capital to expand its horizons. The Spanish company, which launched a solution to treat chronic constipation, has opened a $2.3 million (€2 million) financing round , company sources have confirmed. The objective is to accelerate its growth in the German market and to raise capital in the Netherlands and the United Kingdom. Currently, the company has already raised $522,000 (€450,000) and, with a view to 2023, Mowoot has its sights set on investing throughout the European Union (EU), optimizing processes, and jumping into the U.S. market. Mowoot offers a non-pharmacological and non-invasive solution to constipation in the form of a CE-certified Class IIa medical device. This device provides an external massage to move stool naturally with a maximum of twenty minutes of daily treatment. The system is already in use in several countries, including Germany, the United Kingdom, the Netherlands, and Spain. Get comprehensive access to global crowdfunding business, biotech investments, stock market, finance news , and trending topics with the Born2Invest app. Our companion app makes it easy for you to keep informed, to intuitively move from story to story, and from section to section. Our clean design lets you read articles without clutter, and use the app with no limits on how many articles you can view. Mowoot offers a non-drug, non-invasive solution to constipation
In Germany alone, the company estimates that half a million people suffer from neurogenic bowel dysfunction. In the European Union (EU) and the United States, this number rises to 120 million patients. Typical solutions such as drugs, invasive devices, or even surgery have proven to be “ineffective and have various side effects,” according to Mowoot. Four out of five people affected by spinal cord injury, multiple sclerosis, or Parkinson’s disease are also considered to be a potential market for the company. In addition, 60% of people over the age of 65 are also potentially affected by severe constipation. In this regard, the annual cost per patient using this device is between $696 (€600) and $870 (€750) and it is between 72% and 90% effective. In contrast, other therapies such as manual massage, the use of laxatives, and surgical solutions require a cost of between 1,000 and 35,000 euros, according to data provided by the company. The annual cost per patient using the Mowoot device is between $696 (€600) and $870 (€750)
The company was founded in Barcelona, but currently, its most important market is Germany. Mowook entered the country through 4M Medical, a distributor of medical devices and pharmaceuticals. The idea of Mowoot was born in 2014 in a postgraduate course promoted by Biocat, the entity that coordinates and promotes the life sciences and health sector in Catalonia, inspired by a master’s degree work at Stanford University. __
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our  disclaimer  for more information. This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these  important disclosures . First published in  PlantaDoce , a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail. Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Mowoot Opens 2 Million Round to Grow in the German Market

Todostartups
Por
19 julio, 2020
El Instituto Europeo de Innovación y Tecnología en Salud ( EIT Health ) ha destinado 5,5 millones de euros para apoyar 11 startups europeas a través del programa Start-up Rescue Instrument . El objetivo de este programa es dar respuesta a la pandemia y apoyar a los emprendedores en un momento en que el capital riesgo podría reducir sus inversiones en este tipo de compañías. Así lo prevé el informe European Startups, avalado por la Comisión Europea y el Parlamento Europeo, que cuantifica en un 30-40% la importancia de los fondos recaudados por las nuevas empresas en Europa mediante el capital riesgo, y alerta del peligro de no abordar dicho impacto habida cuenta de que las startsups europeas emplean a dos millones de personas. Mowoot es la única startup española en la lista de 11 compañías que recibirán financiación dentro del programa Startup Rescue Instrument. En concreto, EIT Health coinvertirá hasta 500.000 euros y se hará con una participación en la compañía. Fundada por el emprendedor Markus Wilhelms, Mowoot ha desarrollado un dispositivo que simula un masaje abdominal para tratar el estreñimiento crónico en pacientes con distintas enfermedades que reducen su movilidad. Para su desarrollo, Mowoot ha contado con la colaboración de los médicos y fisioterapeutas del centro de neuro-rehabilitación Institut Guttmann. A través de cientos de entrevistas con pacientes, los impulsores de la compañía constataron el gran impacto que tiene el estreñimiento crónico en la calidad de vida de las personas con lesión medular u otras patologías neurológicas. Tras meses de investigación, se desarrolló una novedosa solución no-invasiva y no-farmacológica con el objetivo de evitar o reducir el uso de laxantes, y que consiste en un dispositivo que emula el masaje abdominal específico de colon que realizan los terapeutas profesionales para tratar el estreñimiento. Mowoot es una historia de éxito de EIT Health, pues la red de innovadores europeos los ha acompañado desde su inicio y a lo largo de su trayectoria. Los fundadores se conocieron en el programa d·HEALTH Barcelona , un programa europeo para formar a futuros emprendedores e innovadores del sector salud impulsada por el socio de EIT Health Biocat, e inspirada en la metodología del biodiseño de la Universidad de Stanford. Tras esta experiencia, los fundadores identificaron una necesidad clínica no satisfecha y crearon la empresa y el dispositivo Mowoot. A partir de este momento, la startup ha participado en varios programas de EIT Health en los últimos años, según su momento de madurez. En 2016 la compañía fue una de las 12 startups seleccionadas para participar en el Programa EIT Health Headstart /Proof of Concept y llevar su producto al mercado. En 2017, participó en el programa EIT Health Catapult y fue premiada con el voto del público y segundo puesto en los premios del jurado en la categoría Medtech, lo que les permitió acceder a la EIT Health Mentoring and Coaching Network en 2018. En 2019 participaron en Living Labs & Test Beds   y  en el programa Bridgehead Europe para escalar a nuevos mercados europeos. Por último, este 2020 además de recibir el apoyo del Start-up Rescue Instrument, participan también en Bridgehead Global , para llegar a mercados internacionales.

EIT Health se fija en una startup española que combate el estreñimiento

Genesis Ventures lidera la primera ronda de financiación con crowdfunding lanzada por Mowoot
Genesis Ventures lidera la primera ronda de financiación con  crowdfunding lanzada por Mowoot, una tecnológica fundada en el 2014 en  Barcelona especializada en el diseño y la venta de dispositivos médicos  para combatir el estreñimiento de forma no farmacológica. Mowoot,  dirigida por Markus Wilhelms, captará 400.000 euros para conseguir la  homologación de la FDA para su uso en EE.UU

Genesis Ventures lidera la primera ronda de financiación con crowdfunding lanzada por Mowoot

Biocat acts as a strategic agent and catalyst in the construction of the Catalan healthcare and life sciences ecosystem. Biocat aims to dynamize all the stakeholders of the BioRegion (companies, research groups and entities, hospitals and innovation support structures) to transform knowledge and technology into economic growth and to create a social impact.

Biocat

usMIMA signs a collaboration agreement with Biocat and Institut Guttmann .

MOWOOT - Your move to well-being mowoot
usMIMA signs a collaboration agreement with Biocat and Institut Guttmann

German Research Center for Artificial Intelligence

Bellvitge Biomedical Research Institute

Sanofi

Ricoh España

Altran Technologies

Indra Sistemas

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Medical Devices

Companies developing wearable health monitoring solutions (human health only). Companies tagged as #Wearables (*note: this tag may also apply to companies outside the scope of this collection)

Health Monitoring & Diagnostics

Health IT 

Seed

Series A

MOWOOT is a non-pharmacological, non-invasive, no-side-effects solution to chronic constipation in the form of a wearable medical device that emulates the manual abdominal massage techniques of professional therapists.

Name	Work History	Title	Status
Marc Benet Pozo		Founder	Current
Àngel Calzada	German Research Center for Artificial Intelligence	Founder, Chief Financial Officer, Chief Technology Officer	Current
Immaculada Herrero Fresneda	Bellvitge Biomedical Research Institute	Founder, Chief Operating Officer	Current
Markus Wilhelms	Sanofi	Founder, Chief Executive Officer	Current
Josep Molinero Parra	Ricoh España, Altran Technologies, and Indra Sistemas	Chief Financial Officer	Current

Name	Marc Benet Pozo	Àngel Calzada	Immaculada Herrero Fresneda	Markus Wilhelms	Josep Molinero Parra
Work History		German Research Center for Artificial Intelligence	Bellvitge Biomedical Research Institute	Sanofi	Ricoh España, Altran Technologies, and Indra Sistemas
Title	Founder	Founder, Chief Financial Officer, Chief Technology Officer	Founder, Chief Operating Officer	Founder, Chief Executive Officer	Chief Financial Officer
Status	Current	Current	Current	Current	Current

Wells Fargo Success Story

3M Success Story

Platform Overview

MOWOOT

Executives

MOWOOT Management Team

5 Team Members

You May Also Like

Discover the right solution for your team